IL278949B2 - Benzene sulfonamide compounds and their use as medicinal agents - Google Patents

Benzene sulfonamide compounds and their use as medicinal agents

Info

Publication number
IL278949B2
IL278949B2 IL278949A IL27894920A IL278949B2 IL 278949 B2 IL278949 B2 IL 278949B2 IL 278949 A IL278949 A IL 278949A IL 27894920 A IL27894920 A IL 27894920A IL 278949 B2 IL278949 B2 IL 278949B2
Authority
IL
Israel
Prior art keywords
compound
methyl
formula
compounds
amino
Prior art date
Application number
IL278949A
Other languages
English (en)
Hebrew (he)
Other versions
IL278949B1 (en
IL278949A (en
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of IL278949A publication Critical patent/IL278949A/en
Publication of IL278949B1 publication Critical patent/IL278949B1/en
Publication of IL278949B2 publication Critical patent/IL278949B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/50Nitrogen atoms bound to hetero atoms
    • C07D277/52Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL278949A 2018-06-13 2019-06-13 Benzene sulfonamide compounds and their use as medicinal agents IL278949B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862684436P 2018-06-13 2018-06-13
PCT/US2019/037011 WO2019241533A1 (en) 2018-06-13 2019-06-13 Benzenesulfonamide compounds and their use as therapeutic agents

Publications (3)

Publication Number Publication Date
IL278949A IL278949A (en) 2021-01-31
IL278949B1 IL278949B1 (en) 2024-04-01
IL278949B2 true IL278949B2 (en) 2024-08-01

Family

ID=67138087

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278949A IL278949B2 (en) 2018-06-13 2019-06-13 Benzene sulfonamide compounds and their use as medicinal agents

Country Status (23)

Country Link
US (2) US10745392B2 (enExample)
EP (1) EP3807281A1 (enExample)
JP (3) JP7371029B2 (enExample)
KR (1) KR102833674B1 (enExample)
CN (1) CN112262142B (enExample)
AU (1) AU2019285184B2 (enExample)
BR (1) BR112020024729A2 (enExample)
CA (1) CA3103600A1 (enExample)
CL (1) CL2020003197A1 (enExample)
CR (1) CR20200613A (enExample)
EA (1) EA202092719A1 (enExample)
EC (1) ECSP20079861A (enExample)
IL (1) IL278949B2 (enExample)
JO (1) JOP20200304A1 (enExample)
MA (1) MA52888A (enExample)
MX (1) MX2020013317A (enExample)
NI (1) NI202000098A (enExample)
PE (1) PE20211389A1 (enExample)
PH (1) PH12020552111A1 (enExample)
SA (1) SA520420768B1 (enExample)
SG (1) SG11202011862PA (enExample)
UA (1) UA127024C2 (enExample)
WO (1) WO2019241533A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250505T1 (hr) * 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN112262142B (zh) * 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
EP4655291A2 (en) * 2023-01-26 2025-12-03 Merck Sharp & Dohme LLC N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background
CN117510431A (zh) * 2023-11-08 2024-02-06 浙江雅辰药物科技股份有限公司 一种异噻唑-3-酮及其衍生物、合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180162868A1 (en) * 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
US6416780B1 (en) 1997-05-07 2002-07-09 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
DE19907385A1 (de) 1999-02-20 2000-08-24 Boehringer Ingelheim Pharma Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
JP2005162726A (ja) 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1646628A1 (en) 2003-07-08 2006-04-19 Novartis AG Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP1937658A1 (en) 2005-10-06 2008-07-02 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
EP2316829A1 (en) 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2008019967A2 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2009012241A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009099177A1 (ja) 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
KR20110027657A (ko) 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
KR101541086B1 (ko) 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
IN2014CN02959A (enExample) 2011-10-28 2015-07-03 Merck Sharp & Dohme
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9630929B2 (en) * 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
ES2798138T3 (es) 2012-10-15 2020-12-09 Dae Woong Pharma Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
CA2889378A1 (en) 2012-10-26 2014-05-01 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
US9388179B2 (en) 2012-10-26 2016-07-12 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company RORγ調節因子
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
EP3389654B1 (en) 2015-12-18 2023-08-16 Merck Sharp & Dohme LLC Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
US10442778B2 (en) 2016-03-22 2019-10-15 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
HRP20250505T1 (hr) 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
ES2897998T3 (es) 2016-10-27 2022-03-03 Bristol Myers Squibb Co Inhibidores de la acilsulfonamida del NaV1.7
US10968210B2 (en) * 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN112262142B (zh) * 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180162868A1 (en) * 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents

Also Published As

Publication number Publication date
WO2019241533A1 (en) 2019-12-19
JP2021528387A (ja) 2021-10-21
CN112262142B (zh) 2023-11-14
JP2025128218A (ja) 2025-09-02
EP3807281A1 (en) 2021-04-21
JP2023138672A (ja) 2023-10-02
JOP20200304A1 (ar) 2020-11-25
PH12020552111A1 (en) 2021-08-02
KR102833674B1 (ko) 2025-07-14
BR112020024729A2 (pt) 2021-03-23
US20200361927A1 (en) 2020-11-19
AU2019285184A1 (en) 2021-01-28
JP7371029B2 (ja) 2023-10-30
US10745392B2 (en) 2020-08-18
MA52888A (fr) 2021-04-21
MX2020013317A (es) 2021-04-13
AU2019285184B2 (en) 2023-11-16
US11325902B2 (en) 2022-05-10
IL278949B1 (en) 2024-04-01
EA202092719A1 (ru) 2021-03-16
CA3103600A1 (en) 2019-12-19
CL2020003197A1 (es) 2021-04-30
NI202000098A (es) 2021-05-28
US20190382398A1 (en) 2019-12-19
PE20211389A1 (es) 2021-07-27
CN112262142A (zh) 2021-01-22
KR20210019507A (ko) 2021-02-22
CR20200613A (es) 2021-06-10
IL278949A (en) 2021-01-31
SA520420768B1 (ar) 2022-08-30
UA127024C2 (uk) 2023-03-15
SG11202011862PA (en) 2020-12-30
ECSP20079861A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
US11299490B2 (en) Benzenesulfonamide compounds and their use as therapeutic agents
US11325902B2 (en) Benzenesulfonamide compounds and their use as therapeutic agents
US11174268B2 (en) Benzenesulfonamide compouds and their use as therapeutic agents
AU2019331005B2 (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
HK40045271A (en) Benzenesulfonamide compounds and their use as therapeutic agents
HK40016430A (en) Benzenesulfonamide compounds and their use as therapeutic agents
HK40016430B (en) Benzenesulfonamide compounds and their use as therapeutic agents